Haemalogix

HaemaLogiX Pty Ltd, a clinical-stage biotechnology company headquartered in Sydney, Australia, was founded in 2014 by a team including Bryce Carmine and Chief Scientific Officer Dr. Rosanne Dunn. The company concentrates on the development and commercialization of novel immuno-oncology therapies for hematological malignancies, with a primary focus on multiple myeloma and AL amyloidosis. HaemaLogiX's business model is centered on advancing its proprietary drug candidates through clinical trials to validate their safety and efficacy, with the ultimate goal of commercialization through strategic partnerships, licensing deals, or an outright acquisition by a larger pharmaceutical entity. The company has secured significant funding, including a $10 million placement in September 2021, to advance its clinical programs and manufacturing processes.

The core of HaemaLogiX's therapeutic portfolio lies in its highly specific approach to targeting cancer cells. The company has identified unique antigens, Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), which are present on the surface of cancerous plasma cells but not on healthy ones. Their lead product candidate, KappaMab, is a humanized monoclonal antibody designed to bind to KMA, signaling the patient's own immune system to destroy the myeloma cells. Clinical trial data has been promising; a Phase IIb study of KappaMab in combination with the standard-of-care treatment lenalidomide demonstrated a significant improvement in Overall Response Rate (83% vs 45% in the control group) and a 46% reduction in the risk of death. This approach offers the potential for a safer therapy with fewer off-target side effects compared to existing treatments.

Building on its monoclonal antibody technology, HaemaLogiX is expanding its pipeline to include next-generation platforms. The company is actively developing CAR-T cell therapies and bispecific antibodies targeting both KMA and LMA. A notable milestone is the collaboration with Melbourne's Peter MacCallum Cancer Centre to initiate the first Phase I human trial of its KMA.CAR-T cell therapy, aimed at patients with kappa-type multiple myeloma. The company also has LambdaMab in preclinical development for lambda-positive multiple myeloma and AL amyloidosis. With a strong intellectual property position, including numerous patent filings, HaemaLogiX is positioning itself to address significant unmet needs in the treatment of blood cancers.

Keywords: immuno-oncology, multiple myeloma, monoclonal antibodies, CAR-T therapy, blood cancer, AL amyloidosis, KappaMab, LambdaMab, clinical-stage biotech, biopharmaceutical, KMA antigen, LMA antigen, cancer therapy, hematological malignancies, immunotherapy, bispecific antibodies, oncology drug development, cell therapy, B-cell disorders, targeted therapy